Zopiclone improves sleep quality and daytime well-being in insomniac patients

Hajak, Göran; Clarenbach, P.; Fischer, W. K.; Haase, Wolfgang; Rüther, Eckart

doi:10.1097/00004850-199400940-00004

Cited by 50 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[97][98][99][100][101][102][103][104][105][106][107][108][109] These studies were highly varied in design, many utilizing interval scales (as opposed to specific numeric values) for reporting of sleep outcome variables. Some did not include a placebo comparison.…”

Section: Discussionmentioning

confidence: 99%

“…Hajak 104 found no significant difference from placebo in SL "response rate" (SL reduction of > 15 min) for triazolam 0.25 mg. In contrast, Reeves 98 found triazolam 0.25 mg statistically superior to placebo for SL in a geriatric population on subjective ratings of "how much [the drug] helped."…”

Section: Sleep Latencymentioning

confidence: 93%

“…In additional studies, Hajak 104 found no significant difference between triazolam 0.25 mg and placebo in "percentage of responders" for TST (defined as > 20% increase in TST). Ratings for improvement in TST were significantly better for triazolam 0.25 mg than placebo in the Reeves 98 geriatric study.…”

Section: Sleep Latencymentioning

confidence: 96%

“…Very little systematic analysis of adverse effects is available. Hajak 104 reported that "speech disorder" was the only adverse effect, among many, to be significantly more frequent in the triazolam group than in the placebo condition.…”

Section: Quality Of Sleepmentioning

confidence: 99%

See 3 more Smart Citations

0395 Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline

Sateia

Buysse

Krystal

et al. 2017

Sleep

View full text Add to dashboard Cite

Introduction:The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad classes of drugs, this guideline focuses on individual drugs commonly used to treat insomnia. It includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication for this condition. This guideline should be used in conjunction with other AASM guidelines on the evaluation and treatment of chronic insomnia in adults. Methods: The American Academy of Sleep Medicine commissioned a task force of four experts in sleep medicine. A systematic review was conducted to identify randomized controlled trials, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence. The task force developed recommendations and assigned strengths based on the quality of evidence, the balance of benefits and harms, and patient values and preferences. Literature reviews are provided for those pharmacologic agents for which sufficient evidence was available to establish recommendations. The AASM Board of Directors approved the final recommendations. Recommendations:The following recommendations are intended as a guideline for clinicians in choosing a specific pharmacological agent for treatment of chronic insomnia in adults, when such treatment is indicated. Under GRADE, a STRONG recommendation is one that clinicians should, under most circumstances, follow. A WEAK recommendation reflects a lower degree of certainty in the outcome and appropriateness of the patient-care strategy for all patients, but should not be construed as an indication of ineffectiveness. GRADE recommendation strengths do not refer to the magnitude of treatment effects in a particular patient, but rather, to the strength of evidence in published data. Downgrading the quality of evidence for these treatments is predictable in GRADE, due to the funding source for most pharmacological clinical trials and the attendant risk of publication bias; the relatively small number of eligible trials for each individual agent; and the observed heterogeneity in the data. The ultimate judgment regarding propriety of any specific care must be made by the clinician in light of the individual circumstances presented by the patient, available diagnostic tools, accessible treatment options, and resources.1. We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults. (WEAK) 2. We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK) 3. We suggest that clinicians use zaleplon as a treatment for sleep onset insomnia (versus no treatment) in adults. (WEAK) 4. We suggest that clinicians use zolpidem as a treatment for sleep onset and sleep maintenance in...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Sleep Latencymentioning

confidence: 93%

Section: Sleep Latencymentioning

confidence: 96%

Section: Quality Of Sleepmentioning

confidence: 99%

See 2 more Smart Citations

0395 Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline

Sateia

Buysse

Krystal

et al. 2017

Sleep

View full text Add to dashboard Cite

show abstract

“…Comparative studies between zopiclone and benzodiazepines have shown that the hypnotic properties of zopiclone are either equal or superior to those of benzodiazepines (Ngen and Hassan, 1990;Klimm et al, 1990;Autret et al, 1987;Chaudoir et al, 1990;Elie et al, 1990;Hajak et al, 1994;Fleming et al, 1990;Van der Kleijn, 1989;Noble et al, 1998;Hajak, 1999). However, it is through its side effect profile that zopiclone has a real advantage over benzodiazepines.…”

Section: Therapeutic Efficacymentioning

confidence: 99%

Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement

Montplaisir

Hawa

Moller

et al. 2003

Human Psychopharmacology

View full text Add to dashboard Cite

Benzodiazepines and Zolpidem for Chronic Insomnia

Nowell

Mazumdar²,

Buysse³

et al. 1997

JAMA

370

View full text Add to dashboard Cite

Benzodiazepines and zolpidem produced reliable improvements in commonly measured parameters of sleep in patients with chronic insomnia. Relative to the chronic and recurring course of insomnia, both the limited duration of treatments studied and the lack of follow-up data from controlled trials represent challenges for developing evidence-based guidelines for the use of hypnotics in the management of chronic insomnia.

show abstract

Zopiclone improves sleep quality and daytime well-being in insomniac patients

Cited by 50 publications

References 0 publications

0395 Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline

0395 Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline

Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement

Benzodiazepines and Zolpidem for Chronic Insomnia

Contact Info

Product

Resources

About